Lyell Immunopharma, Inc.
For the period ended Aug 6, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 6, 2026 · Filed Aug 6, 2026
Use the contents to explore the available documents and sections.
LYEL$14.86-0.9%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Statement of Operations Data:
Statement of Operations Data:
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue | $4 | $8 | $6 | $15 |
| Operating expenses: | ||||
| Research and development | 39,524 | 34,857 | 76,128 | 78,304 |
| General and administrative | 9,576 | 9,786 | 19,131 | 23,832 |
| Other operating (income) loss, net | (1,759) | 1,062 | (3,655) | 943 |
| Impairment of long-lived assets | — | 1,443 | — | 1,443 |
| Total operating expenses | 47,341 | 47,148 | 91,604 | 104,522 |
| Loss from operations | (47,337) | (47,140) | (91,598) | (104,507) |
| Interest income, net | 2,184 | 3,276 | 4,378 | 7,138 |
| Other income, net | 398 | 1,180 | 18,312 | 2,490 |
| Total other income, net | 2,582 | 4,456 | 22,690 | 9,628 |
| Net loss | $(44,755) | $(42,684) | $(68,908) | $(94,879) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.